Structured around enabling scientists to eliminate disease and suffering through novel application of computational technologies and translating these findings directly and rapidly to clinical use, from its inception in 1997, BioDiscovery had worked in the arena of microarray informatics - among the first dedicated commercial software tool for analyzing microarray images. Since then, innovation has continued to be a top priority. Headquartered in Southern California and having European headquarters in Cambridge, UK. and having limited SBIR involvement, the firm's personnel work on the development of state-of-the-art software products for life science research as well as clinical applications -- providing the tools to scientists for application of computational technologies and to translate these findings directly and rapidly to clinical use. The firm provides a full line of modular software packages spanning image analysis, microarray data processing, and advanced analysis of CNV and expression data built for power -- handling of large scale data. In October 2021, it was announced that Bionano Genomics had acquired Biodiscovery in a $90M cash and stock deal as way to expand its own genomics analysis endeavors. While both companies provide genomics analysis solutions, Bionano personnel indicated that combining its technology with BioDiscoveryâs software would serve to provide the integrated offering that many labs want
